ABBV Raises 2026 Outlook on Stronger Demand and Pipeline Progress
FROM THE WIRE · FINANCE.YAHOO.COM
AbbVie Inc. ABBV raised its 2026 guidance during its third-quarter earnings call, citing sustained demand for its immunology and neuroscience treatments. Management emphasized continued growth from Skyrizi and Rinvoq, alongside expanding opportunities across its development…
Read at the source ↗MARKET IMPACTHIGH✦ News Impact agent estimateTone: expected bullishA major pharma company raised its full-year guidance, a significant signal for the healthcare sector.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01AbbVie now expects approximately $67.8 billion in 2026 revenues, an increase of $200 million.
- 02Adjusted earnings guidance was raised to $13.95-$13.99 per share.
- 03Fourth-quarter revenues are projected at approximately $18.4 billion.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets